Pages that link to "Q21004071"
Jump to navigation
Jump to search
The following pages link to Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg (Q21004071):
Displaying 50 items.
- Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel (Q21261394) (← links)
- Enzyme replacement therapy for Anderson-Fabry disease (Q24200877) (← links)
- Enzyme replacement therapy for Anderson-Fabry disease (Q26471010) (← links)
- Pain management strategies for neuropathic pain in Fabry disease--a systematic review (Q26766561) (← links)
- Agalsidase alfa: a review of its use in the management of Fabry disease (Q28274194) (← links)
- Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease (Q28477142) (← links)
- Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease (Q28748170) (← links)
- Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease? (Q30458149) (← links)
- Stroke and Fabry disease. (Q34061632) (← links)
- Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy (Q34103791) (← links)
- Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome (Q34456578) (← links)
- Enzyme replacement therapy for Fabry disease: some answers but more questions (Q34703815) (← links)
- Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study (Q34739186) (← links)
- Update on role of agalsidase alfa in management of Fabry disease (Q34883178) (← links)
- Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders (Q35009083) (← links)
- Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies (Q35028532) (← links)
- Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. (Q35247511) (← links)
- Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients (Q35560027) (← links)
- Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy (Q35665871) (← links)
- Efficient Uptake of Recombinant α-Galactosidase A Produced with a Gene-Manipulated Yeast by Fabry Mice Kidneys (Q35719001) (← links)
- Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease (Q36025702) (← links)
- Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease (Q36193984) (← links)
- Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment (Q36338254) (← links)
- Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience (Q36433306) (← links)
- Elevated globotriaosylsphingosine is a hallmark of Fabry disease. (Q36498349) (← links)
- Agalsidase benefits renal histology in young patients with Fabry disease (Q36509288) (← links)
- Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage (Q36590963) (← links)
- Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis (Q36607211) (← links)
- Cost-effectiveness of enzyme replacement therapy for Fabry disease (Q36688268) (← links)
- Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. (Q36691965) (← links)
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain (Q36767452) (← links)
- Early therapeutic intervention in females with Fabry disease? (Q37109597) (← links)
- Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults (Q37145860) (← links)
- Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association (Q37251490) (← links)
- Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease (Q37290507) (← links)
- Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease (Q37329223) (← links)
- Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives (Q37494846) (← links)
- Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease (Q37521065) (← links)
- Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. (Q37591813) (← links)
- Enzyme replacement therapy for Fabry disease: a systematic review of available evidence (Q37620334) (← links)
- Vasculopathy in patients with Fabry disease: current controversies and research directions. (Q37630026) (← links)
- Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking (Q37641276) (← links)
- Emerging drugs for lysosomal storage diseases (Q37765901) (← links)
- Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature. (Q37801828) (← links)
- Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). (Q37814691) (← links)
- Fabry disease, enzyme replacement therapy and the significance of antibody responses (Q37950838) (← links)
- Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. (Q37994740) (← links)
- Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature (Q38042191) (← links)
- Fabry disease: raising awareness of the disease among physicians (Q38052848) (← links)
- Gene therapy for fabry disease: a review of the literature (Q38098070) (← links)